Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324049 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
A Phase 1 study of Mucopolysaccharidosis IIIB, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 4
- Study locations
NCT02324049 is a Phase 1 study of Mucopolysaccharidosis IIIB that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 11 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT02324049, a Phase 1 study of Mucopolysaccharidosis IIIB, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 4
- Study locations
Study Summary
Study to evaluate the safety and tolerability of intravenous (IV) administration of SBC-103 in participants with mucopolysaccharidosis III, type B (MPS IIIB, Sanfilippo B) with evaluable signs or symptoms of developmental delay.
Conditions Studied
Interventions
- DRUG SBC-103
Study Locations (4)
Other
- - Barcelona
- - Birmingham
Minnesota
- - Minneapolis
Pennsylvania
- - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-01-22 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02324049
The ClinicalTrials.gov registry entry for NCT02324049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mucopolysaccharidosis IIIB appearing as the primary indexed condition, and to 1 intervention - of which SBC-103 is the first listed.
NCT02324049 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02324049 about?
NCT02324049 is a clinical study titled "Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)". Study to evaluate the safety and tolerability of intravenous (IV) administration of SBC-103 in participants with mucopolysaccharidosis III, type B (MPS IIIB, Sanfilippo B) with evaluable signs or symptoms of developmental delay.
What is the current status of trial NCT02324049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2015-01-22. Estimated completion is 2017-10-16.
What conditions does trial NCT02324049 study?
This clinical trial studies the following conditions: Mucopolysaccharidosis IIIB.
What interventions are being tested in trial NCT02324049?
The interventions under investigation include: SBC-103 (DRUG).
Who is sponsoring clinical trial NCT02324049?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02324049 being conducted?
This trial has 4 study locations across Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.